Therefore, sophisticated design is necessary and caution has to be taken when administrating and handling Nrf2-dependent (as discussed above) phytochemicals in cancer patients, given that transformed cancer cells that are “overprotected” by antioxidants could possibly develop drug resistance. Here, NFE2L2 is linked to cancer.